EUVIMEDEUVIMED entdecken
Crossref

Cost Effectiveness of Adding Fenfluramine to Standard of Care for Patients with Dravet Syndrome in Sweden

Chiara Malmberg iD, Magnus Värendh, Patric Berling, Mata Charokopou, Erik Eklund

Applied Health Economics and Health Policy · 2024

DOI: 10.1007/s40258-024-00886-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Applied Health Economics and Health Policy, 2024. Verfasst von Chiara Malmberg und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Swedish Institute for Health Economics (IHE), Lund, Sweden. chiara.malmberg@ihe.se. Hauptthemen laut MEDLINE: Epilepsies, Myoclonic, Cost-Benefit Analysis, Fenfluramine, Standard of Care. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: UCB Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study evaluated, in a Swedish setting, the cost effectiveness of fenfluramine (FFA) as an add-on to standard of care (SoC) for reducing seizure frequency in Dravet syndrome, a severe developmental epileptic encephalopathy. METHODS: Cost effectiveness of FFA+SoC compared with SoC only was evaluated using a patient-level simulation model with a lifetime horizon. Patient characteristics and treatment effects, including convulsive seizures, seizure-free days and mortality, were derived from FFA clinical trials. Resource use and costs included cost of drug acquisition, routine care and monitoring, as well as ongoing and emergency resources. Quality of life (QoL) estimates for patients and their caregivers were derived from clinical trial data. Robustness was evaluated by one-way sensitivity analysis, probabilistic sensitivity analysis and scenario analyses. RESULTS: Lifetime cost of FFA+SoC was ~3 million SEK per patient compared with ~1.5 million SEK for SoC only. FFA+SoC generated 15% more QALYs than SoC only (21.2 vs 18.5 over a lifetime), resulting in an incremental cost-effectiveness ratio (ICER) of ~540,000 SEK. Moreover, FFA+SoC had a higher probability of being cost effective than SoC only from a willingness-to-pay threshold of 710,000 SEK. Results remained generally consistent across scenario analyses, with only few exceptions (exclusions of carer utility or FFA effect on sudden unexpected death in epilepsy). CONCLUSION: Due to better seizure control, FFA is a clinically meaningful add-on therapy and was estimated to be a cost-effective addition to current SoC for patients with this rare disease in Sweden at a willingness-to-pay threshold of 1,000,000 SEK.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epilepsies, MyoclonicCost-Benefit AnalysisFenfluramineStandard of CareHumansSwedenFemaleMaleQuality-Adjusted Life YearsAnticonvulsantsAdultAdolescentChildQuality of LifeYoung AdultCost-Effectiveness Analysis

Substanzen

FenfluramineAnticonvulsants

Autor:innen und Institutionen

  • The Swedish Institute for Health Economics (IHE), Lund, Sweden. chiara.malmberg@ihe.se.
  • The Swedish Institute for Health Economics (IHE), Lund, Sweden.
  • UCB Pharma, Stockholm, Sweden.
  • UCB Pharma, Brussels, Belgium.
  • Clinical Sciences, Pediatric Neurology, Lund University, Lund, Sweden.

ORCID-Profile: Chiara Malmberg

Förderung

  • UCB Pharma

Zitieren

APA

Malmberg, C., Värendh, M., Berling, P., Charokopou, M., & Eklund, E. (2024). Cost Effectiveness of Adding Fenfluramine to Standard of Care for Patients with Dravet Syndrome in Sweden. Applied Health Economics and Health Policy. https://doi.org/10.1007/s40258-024-00886-0

Vancouver

Malmberg C, Värendh M, Berling P, Charokopou M, Eklund E. Cost Effectiveness of Adding Fenfluramine to Standard of Care for Patients with Dravet Syndrome in Sweden. Applied Health Economics and Health Policy. 2024. doi:10.1007/s40258-024-00886-0

BibTeX
@article{Malmberg2024,
  author = {Malmberg, Chiara and Värendh, Magnus and Berling, Patric and Charokopou, Mata and Eklund, Erik},
  title = {Cost Effectiveness of Adding Fenfluramine to Standard of Care for Patients with Dravet Syndrome in Sweden},
  journal = {Applied Health Economics and Health Policy},
  year = {2024},
  doi = {10.1007/s40258-024-00886-0}
}
Kostenlos starten →